.png)
Circulating Tumor Cells (CTC) Market By Technology (CTC Analysis, CTC Enrichment and CTC Detection), By Application (EMT biomarkers development, Tumorigenesis research, Cancer stem cell research and others) - Global Industry Analysis & Forecast to 2027
Published On : August 2018 Pages : 180 Category: Biotechnology Report Code : HC081232
SEGMENTS & REGIONS:
- By Technology: CTC Analysis, CTC Enrichment and CTC Detection
- By Application: EMT biomarkers development, Tumorigenesis research, Cancer stem cell research and others
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Outlook and Trend Analysis
The Circulating Tumor Cells (CTC) Market is expected to gain considerable market share by 2027, while registering itself at a significant compound annual growth rate (CAGR) during the forecast period. Circulating tumor cells are essentially helpful in deciding the status of disease progression rate and projection of treatment required for the elimination of the tumor. Further advancement of different tumor markers that can be useful alongside diagnostics to monitor or analyze different types of cancer are foreseen to support use rates of CTC tests in the coming years. Circling tumor cell detection test has the capacity to quantify, detect, and analyze tumor cells in the blood of cancer patients. It incorporates detection, enrichment and examination of the distinguished circulating tumor cells.
Technology Outlook and Trend Analysis
CTC enrichment procedures have involved a market income share of more than % of the aggregate market it is foreseen that it will witness lucrative development over the gauge time frame and these methods for CTC detection incorporate enrichment by making use of magnetic beads, filtration, centrifugal force, and other physical properties, for example, electric charges, size, deformity, and density. Development of enriched CTCs empowers their operational characterization which is fundamental for disease cross examination and target treatment thereby prompting ascend in development of interest for enrichment technology.
Application Outlook and Trend Analysis
The detection of CTC has turned out to be strong and reproducible with the advent of novel technology, for example, capturing CTC groups from the unprocessed blood by making use of molecular biology techniques. Standardization in process, which is instrumental for the assistance of multicenter trials, has driven the elated clinical utility of CTC. Research activities conducted by different organizations to find efficient and high yielding CTC collection procedures is additionally set to enable the market to develop in the upcoming years.
Regional Outlook and Trend Analysis
North America has had the commanding share of the overall industry in the market. It held the share of more than % in 2017. Existence of major players, increasing awareness levels of patients, Increasing R&D activities relating to drug discovery are certain aspects in charge of its extensive share. Asia Pacific is foreseen to encounter a considerable development throughout the following decade with a significant CAGR inferable from the expanding frequencies of cancer among the emerging nations in the district that can be ascribed to the aging populace and changing way of life related with increasing discretionary income.
Competitive Insights
The major players in the market are Biocept, ScreenCell, Biofluidica Inc, Fluxion Biosciences, Advanced Cell Diagnostics, Greiner Bio-One, Aviva Biosciences, Epic Sciences, Janssen Diagnostics, Clearbridge BioMedics Pte Ltd and CellTraffix Inc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The Circulating Tumor Cells (CTC) Market is segmented as follows-
By Technology
- CTC Analysis
- CTC Detection
- Immunocytochemical technologies
- Xenotransplantation models
- Molecular(RNA) based technologies
- EPISPOT functional in-vitro cell culture
- Functional in-vitro cell invasion assay
- CTC Enrichment
- Negative selection
- Ex-vivo positive selection
- Single spiral micro channel
- In-vivo positive selection
- Microchips
By Application
- Cancer stem cell research
- EMT biomarkers development
- Tumorigenesis research
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Circulating Tumor Cells (CTC) Market, By Technology, Estimates and Forecast, 2017-2027 ($Million)
· CTC Analysis
· CTC Enrichment
· CTC Detection
· Circulating Tumor Cells (CTC) Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
· EMT biomarkers development
· Tumorigenesis research
· Cancer stem cell research
· others
· Circulating Tumor Cells (CTC) Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
· North America
§ North America Circulating Tumor Cells (CTC) Market, By Country
o U.S. Circulating Tumor Cells (CTC) Market
o Canada Circulating Tumor Cells (CTC) Market
o Mexico Circulating Tumor Cells (CTC) Market
· Europe
§ Europe Circulating Tumor Cells (CTC) Market, By Country
o Germany Circulating Tumor Cells (CTC) Market
o UK Circulating Tumor Cells (CTC) Market
o France Circulating Tumor Cells (CTC) Market
o Russia Circulating Tumor Cells (CTC) Market
o Italy Circulating Tumor Cells (CTC) Market
o Rest of Europe Circulating Tumor Cells (CTC) Market
· Asia-Pacific
§ Asia-Pacific Circulating Tumor Cells (CTC) Market, By Country
o China Circulating Tumor Cells (CTC) Market
o Japan Circulating Tumor Cells (CTC) Market
o South Korea Circulating Tumor Cells (CTC) Market
o India Circulating Tumor Cells (CTC) Market
o Southeast Asia Circulating Tumor Cells (CTC) Market
o Rest of Asia-Pacific Circulating Tumor Cells (CTC) Market
· South America
§ South America Circulating Tumor Cells (CTC) Market
o Brazil Circulating Tumor Cells (CTC) Market
o Argentina Circulating Tumor Cells (CTC) Market
o Columbia Circulating Tumor Cells (CTC) Market
o Rest of South America Circulating Tumor Cells (CTC) Market
· Middle East and Africa
§ Middle East and Africa Circulating Tumor Cells (CTC) Market
o Saudi Arabia Circulating Tumor Cells (CTC) Market
o UAE Circulating Tumor Cells (CTC) Market
o Egypt Circulating Tumor Cells (CTC) Market
o Nigeria Circulating Tumor Cells (CTC) Market
o South Africa Circulating Tumor Cells (CTC) Market
o Rest of MEA Circulating Tumor Cells (CTC) Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2027)
4.1.2. Canada Market States and Outlook (2017-2027)
4.1.3. Mexico Market States and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2027)
4.2.2. France Market States and Outlook (2017-2027)
4.2.3. UK Market States and Outlook (2017-2027)
4.2.4. Russia Market States and Outlook (2017-2027)
4.2.5. Italy Market States and Outlook (2017-2027)
4.2.6. Rest of Europe Market States and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2027)
4.3.2. Japan Market States and Outlook (2017-2027)
4.3.3. Korea Market States and Outlook (2017-2027)
4.3.4. India Market States and Outlook (2017-2027)
4.3.5. Southeast Asia Market States and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market States and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2027)
4.4.2. Argentina Market States and Outlook (2017-2027)
4.4.3. Columbia Market States and Outlook (2017-2027)
4.4.4. Rest of South America Market States and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2027)
4.5.2. United Arab Emirates Market States and Outlook (2017-2027)
4.5.3. Egypt Market States and Outlook (2017-2027)
4.5.4. Nigeria Market States and Outlook (2017-2027)
4.5.5. South Africa Market States and Outlook (2017-2027)
4.5.6. Turkey Market States and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market States and Outlook (2017-2027)
5. Circulating Tumor Cells (CTC) Market, By Technology
5.1. Introduction
5.2. Global Circulating Tumor Cells (CTC) Revenue and Market Share by Technology (2017-2027)
5.2.1. Global Circulating Tumor Cells (CTC) Revenue and Revenue Share by Technology (2017-2027)
5.3. CTC Analysis
5.3.1. Global CTC Analysis Revenue and Growth Rate (2017-2027)
5.4. CTC Detection
5.4.1. Global CTC Detection Revenue and Growth Rate (2017-2027)
5.4.2. Global CTC Detection By Type
5.4.3. Immunocytochemical technologies
5.4.3.1. Global Immunocytochemical technologies Revenue and Growth Rate (2017-2027)
5.4.4. Xenotransplantation models
5.4.4.1. Global Xenotransplantation models technologies Revenue and Growth Rate (2017-2027)
5.4.5. Molecular(RNA) based technologies
5.4.5.1. Global Molecular(RNA) based technologies Revenue and Growth Rate (2017-2027)
5.4.6. EPISPOT functional in-vitro cell culture
5.4.6.1. Global EPISPOT functional in-vitro cell culture Revenue and Growth Rate (2017-2027)
5.4.7. Functional in-vitro cell invasion assay
5.4.7.1. Global Functional in-vitro cell invasion assay Revenue and Growth Rate (2017-2027)
5.5. CTC Enrichment
5.5.1. Global CTC Enrichment Revenue and Growth Rate (2017-2027)
5.5.2. Global CTC Enrichment By Type
5.5.3. Negative selection
5.5.3.1. Global Negative selection Revenue and Growth Rate (2017-2027)
5.5.4. Ex-vivo positive selection
5.5.4.1. Global Ex-vivo positive selection Revenue and Growth Rate (2017-2027)
5.5.5. Single spiral micro channel
5.5.5.1. Global Single spiral micro channel Revenue and Growth Rate (2017-2027)
5.5.6. In-vivo positive selection
5.5.6.1. Global In-vivo positive selection Revenue and Growth Rate (2017-2027)
5.5.7. Microchips
5.5.7.1. Global Microchips Revenue and Growth Rate (2017-2027)
6. Circulating Tumor Cells (CTC) Market, By Application
6.1. Introduction
6.2. Global Circulating Tumor Cells (CTC) Revenue and Market Share by Application (2017-2027)
6.2.1. Global Circulating Tumor Cells (CTC) Revenue and Revenue Share by Application (2017-2027)
6.3. Cancer stem cell research
6.3.1. Global Cancer stem cell research Revenue and Growth Rate (2017-2027)
6.4. EMT biomarkers development
6.4.1. Global EMT biomarkers development Revenue and Growth Rate (2017-2027)
6.5. EMT biomarkers development
6.5.1. Global EMT biomarkers development Revenue and Growth Rate (2017-2027)
6.6. Others
6.6.1. Global Others Revenue and Growth Rate (2017-2027)
7. Circulating Tumor Cells (CTC) Market, By Region
7.1. Introduction
7.2. Global Circulating Tumor Cells (CTC) Revenue and Market Share by Regions
7.2.1. Global Circulating Tumor Cells (CTC) Revenue by Regions (2017-2027)
7.3. North America Circulating Tumor Cells (CTC) by Countries
7.3.1. North America Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2027)
7.3.2. North America Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Circulating Tumor Cells (CTC) by Countries
7.4.1. Europe Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2027)
7.4.2. Europe Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Circulating Tumor Cells (CTC) by Countries
7.5.1. Asia-Pacific Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Circulating Tumor Cells (CTC) by Countries
7.6.1. South America Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2027)
7.6.2. South America Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Circulating Tumor Cells (CTC) by Countries
7.7.1. Middle East and Africa Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Biocept
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. ScreenCell
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. Biofluidica Inc
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Fluxion Biosciences
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. Advanced Cell Diagnostics
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. Greiner Bio-One
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. Aviva Biosciences
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. Epic Sciences
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
8.9. Janssen Diagnostics
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Revenue and Market Share
8.10. Clearbridge BioMedics Pte Ltd
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Revenue and Market Share
8.11. CellTraffix Inc
8.11.1. Business Overview
8.11.2. Service Portfolio
8.11.3. Strategic Developments
8.11.4. Revenue and Market Share
9. Global Circulating Tumor Cells (CTC) Market Competition, by Manufacturer
9.1. Global Circulating Tumor Cells (CTC) Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Circulating Tumor Cells (CTC) Price By Region (2017-2017)
9.3. Top 5 Circulating Tumor Cells (CTC) Manufacturer Market Share
9.4. Market Competition Trend
10. Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.1. Global Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Circulating Tumor Cells (CTC) Market Forecast by Regions (2017-2027)
10.2.1. North America Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.1.1. United States Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.1.2. Canada Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.1.3. Mexico Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2. Europe Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2.1. Germany Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2.2. France Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2.3. UK Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2.4. Russia Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2.5. Italy Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3. Asia-Pacific Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3.1. China Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3.2. Japan Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3.3. Korea Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3.4. India Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.4. South America Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.4.1. Brazil Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.4.2. Argentina Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.4.3. Columbia Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.4.4. Rest of South America Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5. Middle East and Africa Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.3. Egypt Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.4. Nigeria Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.5. South Africa Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.6. Turkey Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Circulating Tumor Cells (CTC) Market Forecast (2017-2027)
10.3. Circulating Tumor Cells (CTC) Market Forecast by Technology (2017-2027)
10.3.1. Circulating Tumor Cells (CTC) Forecast by Technology (2017-2027)
10.3.2. Circulating Tumor Cells (CTC) Market Share Forecast by Technology (2017-2027)
10.4. Circulating Tumor Cells (CTC) Market Forecast by Application (2017-2027)
10.4.1. Circulating Tumor Cells (CTC) Forecast by Application (2017-2027)
10.4.2. Circulating Tumor Cells (CTC) Market Share Forecast by Application (2017-2027)
List of Tables
11. List of Tables and Figures
Figure United States Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Circulating Tumor Cells (CTC) Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Circulating Tumor Cells (CTC) Revenue and Revenue Share by Technology (2017-2018)
Figure Global CTC Analysis Revenue and Growth Rate (2017-2018)
Figure Global CTC Detection Revenue and Growth Rate (2017-2018)
Figure Global CTC Enrichment Revenue and Growth Rate (2017-2018)
Table Global Circulating Tumor Cells (CTC) Revenue and Revenue Share by Application (2017-2018)
Figure Global Cancer stem cell research Revenue and Growth Rate (2017-2018)
Figure Global EMT biomarkers development Revenue and Growth Rate (2017-2018)
Figure Global EMT biomarkers development Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Circulating Tumor Cells (CTC) Revenue by Regions (2017-2018)
Figure North America Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure North America Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2018)
Figure North America Circulating Tumor Cells (CTC) by Countries (2017-2018)
Figure North America Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2018)
Figure United States Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure United States Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Canada Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Mexico Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Europe Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2018)
Figure Europe Circulating Tumor Cells (CTC) by Countries (2017-2018)
Figure Europe Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2018)
Figure Germany Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Germany Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure France Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure UK Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Russia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Italy Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Rest of Europe Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Asia-Pacific Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Circulating Tumor Cells (CTC) by Countries (2017-2018)
Figure Asia-Pacific Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2018)
Figure China Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure China Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Japan Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Korea Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure India Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Southeast Asia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure South America Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2018)
Figure South America Circulating Tumor Cells (CTC) by Countries (2017-2018)
Figure South America Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Brazil Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Argentina Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Columbia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Rest of South America Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Middle East and Africa Circulating Tumor Cells (CTC) Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Circulating Tumor Cells (CTC) by Countries (2017-2018)
Figure Middle East and Africa Circulating Tumor Cells (CTC) Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Saudi Arabia Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure United Arab Emirates Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Egypt Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Nigeria Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure South Africa Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Turkey Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Circulating Tumor Cells (CTC) Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2017-2018)
Table Biocept Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table ScreenCell Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biofluidica Inc Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Fluxion Biosciences Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Advanced Cell Diagnostics Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Greiner Bio-One Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Aviva Biosciences Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Epic Sciences Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Janssen Diagnostics Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Clearbridge BioMedics Pte Ltd Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table CellTraffix Inc Circulating Tumor Cells (CTC) Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Circulating Tumor Cells (CTC) Market Share by Manufacturer
Figure Global Circulating Tumor Cells (CTC) Revenue and Market Share by Manufacturer
Table Global Circulating Tumor Cells (CTC) Price by Region (2017-2017)
Figure Top 5 Circulating Tumor Cells (CTC) Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Circulating Tumor Cells (CTC) Revenue (Millions USD) and Growth Rate (2018-2025)
Table Circulating Tumor Cells (CTC) Market Forecast by Regions (2018-2025)
Figure North America Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure United States Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Canada Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Mexico Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Europe Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Germany Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure France Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure UK Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Russia Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Italy Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Rest of Europe Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Asia-Pacific Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure China Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Japan Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Korea Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure India Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Southeast Asia Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure South America Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Brazil Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Argentina Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Columbia Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Rest of South America Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Middle East and Africa Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Saudi Arabia Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure United Arab Emirates Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Egypt Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Nigeria Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure South Africa Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Turkey Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Circulating Tumor Cells (CTC) Market Forecast (2018-2025)
Figure Global Circulating Tumor Cells (CTC) Forecast by Technology (2018-2025)
Figure Global Circulating Tumor Cells (CTC) Market Share Forecast by Technology (2018-2025)
Figure Global Circulating Tumor Cells (CTC) Forecast by Technology (2018-2025)
Figure Global Circulating Tumor Cells (CTC) Forecast by Application (2018-2025)
Figure Global Circulating Tumor Cells (CTC) Market Share Forecast by Application (2018-2025)
Figure Global Circulating Tumor Cells (CTC) Forecast by Application (2018-2025)
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|